The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Abstract
PURPOSE: To determine whether granulocyte colony-stimulating factor (G-CSF) administered before, during, and after fludarabine plus cytarabine (ara-C; FA) chemotherapy affected complete response (CR) rate, infection rate, blood count recovery, or survival in patients with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). PATIENTS AND METHODS: A total of 112 patients with newly diagnosed AML (n = 69) or MDS (n = 43) received G-CSF 400 micrograms/m2/d 1 day before (presenting WBC count < 50,000/microL) and/or during (all patients) fludarabine 30 mg/m2/d and ara-C 2 g/m2/d for 5 days (FLAG). G-CSF continued until a CR was achieved. Results were compared with those in 85 newly diagnosed patients (54 AML, 31 MDS) previously treated with FA without G-CSF. RESULTS: Patients in both groups were relatively old (median age of all patients, 63 years), and were likely to have prognostically unfavorable cytogenetic abnormalities (36% had abnormalities of chromosomes 5 and 7 [-5/-7]). G-CSF accelerated recovery to > or = 1,000 neutrophils (P < .0001; median, 34 days for FA, 21 days for FLAG), but logistic regression provided no evidence that the CR rate was higher with FLAG than with FA (P = .50), with unadjusted CR rates of 63% and 53%, respectively. This may reflect relatively high rates of death before neutrophil recovery in both groups. Rates of infection were similar in both groups. The follow-up duration in remission is short, and much of these data remain censored. To date, survival is similar with FA and FLAG. CONCLUSION: On average, G-CSF before, during, and after FA had no effect on CR or infection rates in this population, in which elderly patients and poor prognostic factors were prevalent. The use of FA and laminar airflow rooms rather than more usual therapy needs to be considered when analyzing the results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Logistic Regression Diagnostics
Pregibon, D. (1981) · The Annals of Statistics · doi:10.1214/aos/1176345513 · Cited by 1,290
Martingale-based residuals for survival models
THERNEAU, T. M., GRAMBSCH, P. M., & FLEMING, T. R. (1990) · Biometrika · doi:10.1093/biomet/77.1.147 · Cited by 1,099
Gandhi, V, Estey, E., Keating, M. J., & Plunkett, W. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.116 · Cited by 331
Self-citationBuchner, T., Hiddemann, W., Koenigsmann, M., Zuhlsdorf, M., Wormann, B., Boeckmann, A., Freire, E., Innig, G., Maschmeyer, G., & Ludwig, W. (1991) · Blood · doi:10.1182/blood.v78.5.1190.1190 · Cited by 167
Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia
Estey, E., Plunkett, W., Gandhi, V., Rios, M. B., Kantarjian, H., & Keating, M. J. (1993) · Leukemia & Lymphoma · doi:10.3109/10428199309148532 · Cited by 158
Self-citationEstey, E. H., Thall, P., Kantarjian, H. M., O'Brien, S. M., Koller, C., Beran, M., Gutterman, J. U., Deisseroth, A. B., & Keating, M. J. (1992) · Blood · doi:10.1182/blood.v79.9.2246.2246 · Cited by 150
Self-citation
Cited by
Filgrastim (r-metHuG-CSF): the first 10 years
Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G. (1996) · Blood · doi:10.1182/blood.v88.6.1907.bloodjournal8861907 · Cited by 599
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Metastasis prevention by targeting the dormant niche
Ghajar, C. M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3910 · Cited by 320
Kantarjian, H., Gandhi, V., Cortes, J., Verstovsek, S., Du, M., Garcia-Manero, G., Giles, F., Faderl, S., O'Brien, S., Jeha, S., et al. (2003) · Blood · doi:10.1182/blood-2003-03-0925 · Cited by 314
Self-citationDombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322504 · Cited by 308
Metadata
- Authors
- Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., & Kornblau, S.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-04
- Volume
- 12
- Issue
- 4
- Pages
- 671-678
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1857665725
- Cited by
- 294
- References
- 14
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. https://app.cochat.ai/papers/10.1200/jco.1994.12.4.671
- The paper
- Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., & Kornblau, S. (1994). Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.4.671
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.